Sarissa Capital Management LP Innoviva, Inc. Transaction History

Sarissa Capital Management LP

$592 Million
Q2 2024

A detailed history of Sarissa Capital Management LP transactions in Innoviva, Inc. stock. As of the latest transaction made, Sarissa Capital Management LP holds 7,277,000 shares of INVA stock, worth $141 Million. This represents 20.14% of its overall portfolio holdings.

Number of Shares

7,277,000

Previous 7,277,000 -0.0%

Holding current value

$141 Million

Previous $111 Million 7.61%

% of portfolio

20.14%

Previous 19.4%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$11.39 - $13.72 $7.55 Million - $9.1 Million	663,000 Added 10.02%	7,277,000 $92.6 Million
Q3 2021 Nov 15, 2021	BUY	$13.06 - $17.24 $2.61 Million - $3.45 Million	200,000 Added 3.12%	6,614,000 $111 Million
Q2 2020 Aug 14, 2020	BUY	$11.49 - $15.26 $1.98 Million - $2.62 Million	172,000 Added 2.76%	6,414,000 $89.7 Million
Q2 2019 Aug 14, 2019	BUY	$13.1 - $14.95 $2.83 Million - $3.23 Million	215,900 Added 3.58%	6,242,000 $90.9 Million
Q1 2019 May 15, 2019	BUY	$13.69 - $20.06 $13.3 Million - $19.6 Million	975,000 Added 19.3%	6,026,100 $84.5 Million
Q4 2018 Feb 14, 2019	BUY	$13.96 - $18.26 $7.2 Million - $9.42 Million	516,100 Added 11.38%	5,051,100 $88.1 Million
Q2 2018 Aug 14, 2018	BUY	$13.44 - $17.59 $11.8 Million - $15.4 Million	874,295 Added 23.88%	4,535,000 $62.6 Million
Q4 2017 Feb 23, 2018	BUY	$11.73 - $14.75 $703,800 - $885,000	60,000 Added 1.67%	3,660,705 $51.9 Million
Q3 2017 Nov 14, 2017	BUY	$12.06 - $14.12 $43.4 Million - $50.8 Million	3,600,705	3,600,705 $50.8 Million

Others Institutions Holding INVA

# of Institutions

222

Shares Held

79.7M

Call Options Held

20K

Put Options Held

5.4K

View Full List

About Innoviva, Inc.

Ticker INVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,706,000
Market Cap $1.35B
Description
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...

More about INVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Sarissa Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Sarissa Capital Management LP with notifications on news.

Account

Sarissa Capital Management LP Innoviva, Inc. Transaction History